SGCB and systemic sclerosis: Avenciguat (BI 685509) is an sGC activator that has been shown to function under conditions of persistent oxidative stress (Figure 1(b)).19 Preclinical data in mouse models of SSc have shown that avenciguat significantly reduces bleomycin-induced skin and lung fibrosis in a dose-dependent manner and also reduces the levels of cytokines and chemokines that contribute to microvasculopathy, immune dysregulation and fibrosis.